← Back to headlines
FDA Requires Lilly to Conduct Post-Marketing Studies for Obesity Pill
The U.S. Food and Drug Administration has mandated that pharmaceutical company Lilly perform post-marketing studies for its obesity medication.
14 Apr, 13:16 — 14 Apr, 13:16
Sources
Showing 1 of 1 sources
Related Stories
Cyclospora Outbreak Linked to Iceberg Lettuce Expands to Three Additional States
3h ago
Australian Woman Gives Birth to Twins Fathered by Two Different Men
5h ago
U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
9h ago
West Nile Virus Outbreaks Spread Across Greece and North Macedonia
10h ago